Argos Not Stopping Cancer Vaccine Study Despite Futility
Executive Summary
The biotech suggests that ADAPT trial design was not ideally structured to show the longer-term benefit that might result from its autologous immunotherapy. Argos plans to discuss its plan with FDA in May, despite analyst skepticism.
You may also be interested in...
The Year's Clinical Trials In Review: Big Misses In 2017
The big clinical trial setbacks hurt. Scrip takes a look back at the painful clinical trial failures this year, with Axovant's intepirdine and Celgene's mongersen topping the list.
Argos Says FDA Willing To ADAPT To Longer Follow-Up For Immunotherapy
Argos Therapeutics reports FDA support for its plan to continue its ADAPT trial of rocapuldencel-T for metastatic renal cell carcinoma despite a futility finding by the independent data monitoring committee.
Argos And Agenus Trials Pile On Fresh Cancer Vaccine Disappointments
Argos mum on details surrounding Phase III failure of rocapuldencel-T in kidney cancer, while Agenus distances itself from failed Phase II glioblastoma study of Prophage G-200 as an investigator-sponsored trial with a challenging design.